Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. develops thrombectomy technologies for medical conditions involving blood clots, including ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its product portfolio includes computer assisted vacuum thrombectomy and devices such as the Indigo System, Penumbra System Reperfusion Catheter, ACE Reperfusion Catheters, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and Artemis Neuro Evacuation Device.
Recurring company news covers financial results, capital-structure updates, investor conference presentations, and clinical evidence for CAVT in pulmonary embolism and other vascular applications. Updates also include material agreements, shareholder voting matters, governance disclosures, and regulatory or clinical developments tied to Penumbra's thrombectomy and neurovascular products.
Penumbra (NYSE: PEN) reported Q1 2026 revenue of $374.8 million, up 15.6% year-over-year, with thrombectomy revenue $253.9 million (+12.1%) and embolization & access $120.8 million (+23.8%). Gross margin was 67.6%. Operating expenses were $215.2 million (R&D $22.4M; SG&A $192.8M, including $9.4M acquisition-related expenses). Income from operations was $38.2 million and net income $32.6 million. Given the pending acquisition by Boston Scientific (NYSE: BSX), the company will not provide full-year 2026 guidance or host an earnings call.
Penumbra (NYSE: PEN) reported 90-day STORM-PE randomized trial results showing computer assisted vacuum thrombectomy (CAVT) plus anticoagulation produced significantly better functional outcomes versus anticoagulation alone for intermediate-high risk pulmonary embolism.
Key results: 6-minute walk 479m vs 368m (P=0.003); 94% vs 75.2% predicted walk distance (P=0.022); NYHA Class I 97% vs 76% (P=0.022). Safety through 90 days was comparable with no device-related mortality.
Penumbra (NYSE: PEN) reported fourth-quarter 2025 revenue of $385.4M (+22.1%) and full-year 2025 revenue of $1,403.7M (+17.5%). Gross margin improved to 68.0% in Q4 and 67.1% for FY2025. Income from operations was $59.2M in Q4 and $189.2M for FY2025. Net income for Q4 was $47.3M and FY net income was $177.7M. The company will not provide 2026 guidance or host an earnings call due to the proposed acquisition by Boston Scientific (NYSE: BSX).
Boston Scientific (NYSE: BSX) reported strong fourth-quarter 2025 results with Q4 net sales of $5.286 billion (+15.9% reported, +12.7% organic) and GAAP EPS of $0.45 (adjusted EPS $0.80). For full-year 2025, net sales were $20.074 billion (+19.9% reported) and adjusted EPS was $3.06. The company provided 2026 guidance of ~10.5–11.5% reported net sales growth and adjusted EPS of $3.43–3.49. Key developments include FDA/CE approvals for FARAPOINT PFA catheter, launches of SEISMIQ IVL and TheraSphere 360 clearance, enrollment and trial progress across AF, SCS and LAA closure studies, announced acquisitions of Penumbra and Valencia Technologies, and completion of the Nalu Medical acquisition.
Penumbra (NYSE: PEN) provided unaudited, preliminary results for Q4 and full year 2025. Q4 revenue is estimated at $383.0M–$384.8M (+21.4% to +22.0% YoY; +23.2% to +23.8% ex-China). Full-year revenue is estimated at $1,401.3M–$1,403.1M (+17.3% to +17.5% YoY; +24.7% to +24.9% ex-China). Gross margin is ~67.9%–68.1% for Q4 and 67.1% for FY2025. Income from operations is $56.9M–$60.4M (Q4) and $186.9M–$190.4M (FY), implying operating margins of 14.8%–15.7% (Q4) and 13.3%–13.6% (FY).
Boston Scientific (NYSE: BSX) agreed to acquire Penumbra (NYSE: PEN) in a cash-and-stock deal valuing Penumbra at $374 per share, implying an enterprise value of about $14.5 billion. Consideration is ~73% cash and ~27% stock, with a 3.8721 BSX share election per PEN share. Penumbra expects 2025 reported revenue of ~$1.4 billion (growth ~17.3%–17.5%) and Q4 growth ~21.4%–22.0%. Boston Scientific plans to finance roughly $11 billion of the cash portion with cash on hand and new debt. The deal is expected to close in 2026, subject to approvals, and to be mildly dilutive to adjusted EPS by $0.06–0.08 in year one, turning neutral/acc-retive thereafter.
Penumbra (NYSE: PEN) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 6:45pm ET / 3:45pm PT.
A live webcast will be available on the company website under Investors > Events and Presentations and will remain accessible for at least two weeks after the event.
Penumbra (NYSE: PEN) will present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:00 AM ET / 5:00 AM PT. A live webcast will be available via the company’s investor Events and Presentations page at www.penumbrainc.com and will remain on the site for at least two weeks after the event.
Penumbra (NYSE: PEN) reported Q3 2025 revenue of $354.7 million, up 17.8% (16.9% constant currency) versus Q3 2024, with the U.S. representing 77.5% of sales. U.S. revenue rose 21.5%; U.S. thrombectomy sales were $192.0 million, up 18.5%. Gross profit was $240.4 million, or 67.8% gross margin. Income from operations was $48.8 million (13.8% operating margin) and net income was $45.9 million; adjusted EBITDA was $66.7 million (18.8% margin). SG&A increased to $168.9 million. The company raised full‑year 2025 revenue guidance to $1,375 million–$1,380 million (15%–16% growth) and reaffirmed U.S. thrombectomy growth guidance of 20%–21%. A conference call and webcast are scheduled for Nov 5, 2025 at 4:30 PM ET.
Penumbra (NYSE:PEN) announced STORM-PE randomized controlled trial results (Nov 3, 2025) showing that CAVT plus anticoagulation produced significantly greater improvements versus anticoagulation alone in patients with acute intermediate-high risk pulmonary embolism.
Key numeric findings: refined modified Miller score reduction 42.1% vs 15.6% (2.7x; P<0.001), mean heart rate 80.0 vs 86.4 bpm (P=0.022), 90-day six-minute walk 472m vs 376m (P=0.019) and 94% vs 75% predicted walk distance (P=0.022). Safety through 90 days was comparable with no device-related mortality.